NCT04940078View on ClinicalTrials.gov

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 7, 2021

Primary Completion Date

January 19, 2022

Study Completion Date

February 16, 2022

Conditions
Obesity & Overweight
Interventions
DRUG

Cagrilintide

Once weekly doses of cagrilintide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. for 2 weeks

DRUG

semaglutide

Once weekly doses of semaglutide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. over 2 weeks

DRUG

Cagrilintide and semaglutide

Cagrilintide and semaglutide combined and administered using the DV3384 manual syringe

Trial Locations (2)

2860

Novo Nordisk Investigational Site, Søborg

H3P 3P1

Altasciences Company Inc., Montreal

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY